Gland Pharma Gets USFDA Approval for Latanoprost Ophthalmic Solution
1 min read

Gland Pharma Gets USFDA Approval for Latanoprost Ophthalmic Solution

Dailymiorror.News,Hyderabad, December 3, 2024: Gland Pharma Limited, a leading pharmaceutical company specializing in generic injectables, has received approval from the United States Food and Drug Administration (USFDA) for its Latanoprost Ophthalmic Solution, 0.005% (2.5 mL Fill).

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan®, latanoprost ophthalmic solution 0.005% (50 mcg/mL), manufactured by UPJOHN US 2 LLC.

Latanoprost Ophthalmic Solution is indicated for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Gland Pharma plans to launch the product through its marketing partners in FY25. According to IQVIA, the product had US sales of approximately USD 111.6 million for the twelve months ending December 2023.